SCHEMBL6035932

SCHEMBL6035932

COc1ccc(O)c(CC(=O)O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.70
KDM4E B2RXH2 4/20 0.59
POLB P06746 2/20 0.59
MAPT P10636 2/20 0.59
ABL1 P00519 1/20 0.59
RECQL P46063 1/20 0.59
RIN1 Q13671 1/20 0.59
CTDSP1 Q9GZU7 1/20 0.59
MTNR1A P48039 1/20 0.57
MTNR1B P49286 1/20 0.57
PTGS1 P23219 1/20 0.56
AKR1C3 P42330 1/20 0.56
AKR1C2 P52895 1/20 0.56
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
LCK P06239 1/20 0.52
ALDH1A1 P00352 2/20 0.51
GAA P10253 1/20 0.51
TSHR P16473 1/20 0.51
NFKB1 P19838 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19554162 0.94 HSD17B10 (0.62) HSD17B10KDM4EPOLBMAPTABL1
SCHEMBL4081034 0.87 MTNR1A (0.55) HSD17B10KDM4EPOLBMAPTRECQL
SCHEMBL30335932 0.87 POLB (0.73) HSD17B10KDM4EPOLBMAPTABL1
SCHEMBL3296862 0.87 POLB (0.73) HSD17B10KDM4EPOLBMAPTABL1
SCHEMBL8772666 0.86 MTNR1A (0.57) HSD17B10KDM4EPOLBMAPTABL1
SCHEMBL4034916 0.84 MTNR1A (0.56) HSD17B10KDM4EPOLBMAPTMTNR1A
SCHEMBL7368806 0.84 POLB (0.79) HSD17B10POLBMTNR1AMTNR1BCA1
SCHEMBL10834418 0.83 MAPT (0.53) HSD17B10KDM4EPOLBMAPTABL1
SCHEMBL10834420 0.83 MAPT (0.53) HSD17B10KDM4EPOLBMAPTABL1
SCHEMBL30512021 0.82 HSD17B10 (1.00) HSD17B10KDM4EPOLBMAPTABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11406678-B2 Simmondsin formulation Raes, Stefaan (BE) 2022-08-09 US claimed
EP-3452095-B1 SIMMONDSIN FORMULATION Van Den Driessche Herman (BE) 2021-04-07 EP claimed
EP-3452095-A2 SIMMONDSIN FORMULATION Van den Driessche, Herman (BE) 2019-03-13 EP claimed
US-20190070238-A1 SIMMONDSIN FORMULATION VAN DEN DRIESSCHE, HERMAN (BE) 2019-03-07 US claimed
WO-2017191501-A2 SIMMONDSIN FORMULATION D'OOSTERLYNCK ANDRÉ (BE) 2017-11-09 WO claimed
US-20260092045-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2026-04-02 US disclosed
EP-4524133-A2 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2025-03-19 EP disclosed
EP-3939658-B1 SUBSTITUTED BENZOPYRROLE AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS BIOCRYST PHARM INC (US) 2024-10-02 EP disclosed
US-20240294494-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-09-05 US disclosed
US-12043610-B2 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-07-23 US disclosed
US-11866418-B2 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2024-01-09 US disclosed
CN-117164499-A Substituted benzofurans, benzopyrroles, benzothiophenes and structurally related complement inhibitors 拜奥克里斯特制药公司 2023-12-05 CN disclosed
US-20190345135-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2019-11-14 US disclosed
WO-2019195720-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2019-10-10 WO disclosed
WO-2019195720-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2019-10-10 WO disclosed
EP-3452095-A2 SIMMONDSIN FORMULATION Van den Driessche, Herman (BE) 2019-03-13 EP disclosed
US-20190070238-A1 SIMMONDSIN FORMULATION VAN DEN DRIESSCHE, HERMAN (BE) 2019-03-07 US disclosed
US-20190070238-A1 SIMMONDSIN FORMULATION VAN DEN DRIESSCHE, HERMAN (BE) 2019-03-07 US disclosed
WO-2017191501-A2 SIMMONDSIN FORMULATION D'OOSTERLYNCK ANDRÉ (BE) 2017-11-09 WO disclosed
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294494-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS C9, C5, C1QBP HSD17B10 2330/4885KDM4E 2522/4885POLB 3620/4885
US-12043610-B2 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors C9, C5, C1QBP HSD17B10 2330/4885KDM4E 2522/4885POLB 3620/4885
US-20190345135-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS C9, C5, C1QBP HSD17B10 2330/4885KDM4E 2522/4885POLB 3620/4885
US-11866418-B2 Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors C9, C5, C1QBP HSD17B10 2330/4885KDM4E 2522/4885POLB 3620/4885
US-20260092045-A1 SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS TFPI, F3, BTK HSD17B10 4404/4885KDM4E 1536/4885POLB 4835/4885
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 HSD17B10 204/4885KDM4E 509/4885POLB 4532/4885
US-20190070238-A1 SIMMONDSIN FORMULATION SPIN2B, SNCA, CHKB HSD17B10 3292/4885KDM4E 3946/4885POLB 343/4885
US-11406678-B2 Simmondsin formulation SPIN2B, SNCA, CHKB HSD17B10 3292/4885KDM4E 3946/4885POLB 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.